Download Now: 7 Unstoppable Growth Engines of India's $10 Trillion Bull Run...
Here is the latest financial fact sheet of BETA DRUGS . For more details, see the BETA DRUGS quarterly results and BETA DRUGS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -2.9 |
No. of shares | m | 9.61 |
1 Week | % | -5.3 |
1 Month | % | 7.3 |
1 Year | % | 71.9 |
52 week H/L | Rs | 1,595.0/660.0 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
BETA DRUGS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 140 | 124 | 141 | 695 | 1,024 | |
Low | Rs | 57 | 37 | 39 | 119 | 546 | |
Sales per share (Unadj.) | Rs | 76.2 | 94.5 | 120.8 | 191.3 | 236.3 | |
Earnings per share (Unadj.) | Rs | 9.3 | 9.8 | 12.2 | 25.8 | 32.0 | |
Diluted earnings per share | Rs | 8.4 | 9.8 | 12.2 | 25.8 | 32.0 | |
Cash flow per share (Unadj.) | Rs | 12.6 | 13.7 | 19.4 | 33.4 | 42.8 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 47.3 | 59.4 | 71.4 | 96.1 | 127.9 | |
Adj. book value per share | Rs | 42.6 | 59.4 | 71.4 | 96.1 | 127.8 | |
Shares outstanding (eoy) | m | 8.65 | 9.61 | 9.61 | 9.61 | 9.61 | |
Price / Sales ratio | x | 1.3 | 0.9 | 0.7 | 2.1 | 3.3 | |
Avg P/E ratio | x | 10.6 | 8.2 | 7.4 | 15.8 | 24.6 | |
P/CF ratio (eoy) | x | 7.8 | 5.9 | 4.6 | 12.2 | 18.4 | |
Price / Book Value ratio | x | 2.1 | 1.4 | 1.3 | 4.2 | 6.1 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 852 | 774 | 864 | 3,913 | 7,549 | |
Total wages/salary | Rs m | 38 | 69 | 83 | 121 | 171 |
BETA DRUGS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 659 | 908 | 1,161 | 1,838 | 2,271 | |
Other income | Rs m | 4 | 4 | 5 | 8 | 8 | |
Total revenues | Rs m | 663 | 912 | 1,166 | 1,846 | 2,279 | |
Gross profit | Rs m | 118 | 179 | 247 | 427 | 531 | |
Depreciation | Rs m | 28 | 38 | 69 | 73 | 104 | |
Interest | Rs m | 14 | 26 | 24 | 19 | 24 | |
Profit before tax | Rs m | 79 | 120 | 160 | 343 | 411 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | -1 | 26 | 42 | 95 | 103 | |
Profit after tax | Rs m | 80 | 94 | 117 | 248 | 307 | |
Gross profit margin | % | 17.9 | 19.7 | 21.3 | 23.2 | 23.4 | |
Effective tax rate | % | -1.7 | 21.4 | 26.5 | 27.6 | 25.2 | |
Net profit margin | % | 12.2 | 10.4 | 10.1 | 13.5 | 13.5 |
BETA DRUGS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 439 | 573 | 713 | 1,028 | 1,344 | |
Current liabilities | Rs m | 334 | 380 | 366 | 548 | 697 | |
Net working cap to sales | % | 16.0 | 21.3 | 29.9 | 26.1 | 28.5 | |
Current ratio | x | 1.3 | 1.5 | 1.9 | 1.9 | 1.9 | |
Inventory Days | Days | 39 | 28 | 19 | 10 | 11 | |
Debtors Days | Days | 138,563,968 | 128,331,851 | 1,065 | 897 | 1,008 | |
Net fixed assets | Rs m | 394 | 510 | 488 | 602 | 695 | |
Share capital | Rs m | 87 | 96 | 96 | 96 | 96 | |
"Free" reserves | Rs m | 323 | 475 | 590 | 827 | 1,133 | |
Net worth | Rs m | 409 | 571 | 686 | 923 | 1,229 | |
Long term debt | Rs m | 69 | 103 | 111 | 118 | 70 | |
Total assets | Rs m | 834 | 1,083 | 1,201 | 1,630 | 2,039 | |
Interest coverage | x | 6.5 | 5.6 | 7.6 | 19.1 | 18.0 | |
Debt to equity ratio | x | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | |
Sales to assets ratio | x | 0.8 | 0.8 | 1.0 | 1.1 | 1.1 | |
Return on assets | % | 11.4 | 11.1 | 11.8 | 16.4 | 16.2 | |
Return on equity | % | 19.6 | 16.5 | 17.1 | 26.9 | 25.0 | |
Return on capital | % | 19.5 | 21.6 | 23.0 | 34.8 | 33.5 | |
Exports to sales | % | 7.4 | 3.6 | 10.2 | 8.3 | 12.3 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0.2 | |
Exports (fob) | Rs m | 49 | 32 | 118 | 152 | 278 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 5 | |
Fx inflow | Rs m | 49 | 32 | 118 | 152 | 278 | |
Fx outflow | Rs m | 5 | 6 | 3 | 5 | 48 | |
Net fx | Rs m | 44 | 26 | 116 | 147 | 231 |
BETA DRUGS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 1 | 84 | 186 | 296 | 234 | |
From Investments | Rs m | -208 | -151 | -58 | -218 | -191 | |
From Financial Activity | Rs m | 121 | 87 | -77 | -10 | -25 | |
Net Cashflow | Rs m | -86 | 21 | 50 | 69 | 18 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Rahul Batra | COMP SEC: Rajni Brar | YEAR OF INC: 2005 | NSE CODE: 99111114 | FV (Rs): 10 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare BETA DRUGS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Indian share markets reversed the trend as the session progressed and ended the lower. After starting higher on Friday, equity markets had an anti-climatic end today.